Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
RVMD Stock Chart & Stats
$54.10
$0.52(1.17%)
At close: 4:00 PM EST
$54.10
$0.52(1.17%)
Day’s Range― - ―
52-Week Range$29.17 - $62.40
Previous CloseN/A
Volume180.68K
Average Volume (3M)2.16M
Market Cap
$9.29B
Enterprise Value$4.93B
Total Cash (Recent Filing)$2.14B
Total Debt (Recent Filing)$132.79M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 05, 2025EPS Estimate
-1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding186,933,200
10 Day Avg. Volume1,878,054
30 Day Avg. Volume2,160,325
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.98
Enterprise Value/Ebitda-5.58
Forecast
1Y Price Target
$74.92Price Target Upside38.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Clinical DataThe extent and depth of responses for both monotherapy and combination daraxonrasib studies remains comparatively impressive to current chemotherapy treatment options.
Pipeline PotentialRVMD's pan-RAS inhibitor (daraxonrasib) has the potential to change the way pancreatic cancers are treated based on its Ph 1/1b profile.
Regulatory ApprovalDaraxonrasib has been selected as one of the first nine recipients of the new CNPV program, which is awarded to products with significant potential to address a major national priority.
Bears Say
Adverse EventsGrade 3+ adverse events occurred in 58% of patients, notably including anemia, neutrophil count decrease, rash, fatigue, and diarrhea.
Competitive LandscapeCompetitor's data showed an objective response rate slightly exceeding zoldonrasib’s in small patient numbers, limiting the comparison.
Development Path ChallengesRMC-5127 may not follow the same registration path in PDAC due to being early in development and the likely broad penetration of daraxonrasib.
Revolution Medicines News
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $29.17 and its highest was $62.40 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is $9.29B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Nov 05, 2025 which is in 17 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Aug 06, 2025. The company reported -$1.31 earnings per share for the quarter, missing the consensus estimate of -$1.138 by -$0.172.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -1.42.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 186,933,200 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$1.31 in its last earnings report, missing expectations of -$1.138. Following the earnings report the stock price went down -4.69%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in RVMD
Revolution Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.92 (38.48% Upside)
$74.92 (38.48% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 21.4%
Last 30 Days ▲ 21.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.46%
12-Months-Change
Fundamentals
Return on Equity
-46.61%
Trailing 12-Months
Asset Growth
34.35%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc. (RVMD) is a biotechnology company that operates in the pharmaceutical sector, focusing on the discovery and development of novel targeted therapies for cancer. The company is particularly known for its precision oncology approach, targeting specific genetic mutations and pathways that drive cancer growth and progression. Revolution Medicines' core products are centered around inhibiting critical signaling pathways, such as the RAS and mTOR pathways, which are implicated in various types of cancers.
RVMD Company Deck
RVMD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook with significant progress in clinical trials and strategic financial partnerships. However, increased expenses and dependency on regulatory approvals present challenges.View all RVMD earnings summariesRVMD Stock 12 Month Forecast
Average Price Target
$74.92
▲(38.48% Upside)
Technical Analysis
Corcept Therapeutics
―
Ionis Pharmaceuticals
―
Blueprint Medicines
―
Legend Biotech
―
Vaxcyte
―
Ownership Overview
6.40% Insiders
26.68% Mutual Funds
0.05% Other Institutional Investors
54.57% Public Companies and Individual Investors